title: Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
authors: Sang Kyun
authors: SK
authors: Sohn
authors: Joon Ho
authors: JH
authors: Moon
authors: Yoon Young
authors: YY
authors: Cho
authors: Yee Soo
authors: YS
authors: Chae
authors: Jong Gwang
authors: JG
authors: Kim
authors: Kun Soo
authors: KS
authors: Lee
authors: Sun Pyo
authors: SP
authors: Hong
authors: Soo Ok
authors: SO
authors: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate